Aligos Therapeutics (ALGS) Total Current Liabilities (2021 - 2025)
Historic Total Current Liabilities for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $22.0 million.
- Aligos Therapeutics' Total Current Liabilities rose 491.98% to $22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.0 million, marking a year-over-year increase of 491.98%. This contributed to the annual value of $21.7 million for FY2024, which is 907.3% down from last year.
- Per Aligos Therapeutics' latest filing, its Total Current Liabilities stood at $22.0 million for Q3 2025, which was up 491.98% from $20.3 million recorded in Q2 2025.
- Aligos Therapeutics' 5-year Total Current Liabilities high stood at $41.4 million for Q1 2022, and its period low was $18.9 million during Q1 2024.
- In the last 5 years, Aligos Therapeutics' Total Current Liabilities had a median value of $25.2 million in 2021 and averaged $27.0 million.
- In the last 5 years, Aligos Therapeutics' Total Current Liabilities surged by 6390.95% in 2022 and then tumbled by 3276.11% in 2024.
- Over the past 5 years, Aligos Therapeutics' Total Current Liabilities (Quarter) stood at $39.0 million in 2021, then dropped by 14.96% to $33.1 million in 2022, then dropped by 27.84% to $23.9 million in 2023, then decreased by 9.07% to $21.7 million in 2024, then grew by 1.15% to $22.0 million in 2025.
- Its Total Current Liabilities stands at $22.0 million for Q3 2025, versus $20.3 million for Q2 2025 and $18.9 million for Q1 2025.